Arcutis Biotherapeutics(ARQT)

Focus: Arcutis is a public dermatology-focused biotech company founded in 2016, headquartered in Westlake Village, CA, with a single commercial product (ZORYVE) generating $60M in FY2025 revenue.

Dermatology

Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

8-3 this month

Stable — net -3 jobs in 30d

11 added, 14 removed. Backfill posture.

Should You Work at Arcutis Biotherapeutics?

AI assessment

High-risk, high-reward opportunity for risk-tolerant professionals betting on ZORYVE market adoption; viability depends entirely on commercial execution and near-term capital raise.

Why Work Here

Early commercial success with ZORYVE generating $60M revenue in FY2025, up 15x from $4M in FY2024, offering visibility into market traction

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$60M

Key Products

ZORYVE

Dermatology (multiple indications via label expansion)

$7M Part D

Growth

Help build intelligence for Arcutis Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline with 14 programs across roflumilast and proprietary PDE4/JAK inhibitors targeting high-prevalence dermatology indications (psoriasis, eczema, vitiligo)

Recent FDA label expansion for ZORYVE in infants as young as 3 months (July 2026) demonstrates continued regulatory momentum and commercial upside

Watch Out For

Extreme revenue concentration (100% ZORYVE) creates existential dependency on single asset; cash burn of $262M in FY2025 against only $71M cash position signals 3-4 month runway at current burn rate
R&D intensity of 186% ($111M R&D on $60M revenue) is unsustainable long-term; only 12 active job openings and minimal hiring (11 professional, 1 commercial) suggest organizational stress

Generated by Claude from Arcutis Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Flagship product with 15-fold revenue growth YoY and recent FDA approval for infants, establishing market foothold and expansion potential through pediatric label.

ZORYVE

Dermatology (multiple indications)

Peak10.9yr

Alternative formulation with earlier LOE date (2037) suggesting potential lifecycle management strategy or different indication focus.

Pipeline & Clinical Trials

ARQ-154 Foam 0.3%

Psoriasis

Phase 1

Clinical Trials (1)

NCT07340216Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Phase 1

ARQ-234

Atopic Dermatitis (AD)

Phase 1

Clinical Trials (1)

NCT07453602Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Phase 1

ARQ-151 cream 0.15%

Atopic Dermatitis (Eczema)

Phase 1

Clinical Trials (2)

NCT04804605Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Phase 3

NCT04156191Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

ARQ-151- cream 0.3%

Plaque Psoriasis

Phase 1

Clinical Trials (1)

NCT04279119Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

Phase 1

roflumilast

Atopic Dermatitis

Phase 1

ARQ-151 cream 0.5%

Psoriasis

Phase 1/2

Clinical Trials (1)

NCT03392168Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Phase 1/2

ARQ-252 cream 0.3%

Chronic Hand Eczema

Phase 1/2

Clinical Trials (1)

NCT04378569Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Phase 1/2

ARQ-154

Seborrheic Dermatitis

Phase 2

Clinical Trials (4)

NCT04973228Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Phase 3

NCT04128007Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

ARQ-252 cream 0.3%

Vitiligo

Phase 2

Clinical Trials (1)

NCT04811131Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Phase 2

PDE4 inhibitor

Chronic Hand Eczema

Phase 2

ARQ-151 cream 0.3%

Psoriasis

Phase 2

Clinical Trials (1)

NCT04746911Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Phase 2

ARQ-151 cream 0.3%

Psoriasis

Phase 2

Clinical Trials (1)

NCT04655313Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Phase 2

roflumilast

Plaque Psoriasis

Phase 3

Clinical Trials (5)

NCT07560618Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

Phase 4

NCT05028582Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

roflumilast

Seborrheic Dermatitis

Phase 3

Interview Prep Quick Facts

Founded: 2016

Portfolio: 2 approved products, 29 clinical trials

Top TAs: Immunology, Dermatology, Gastroenterology

Publications: 28 in PubMed

SEC Filings: 2 available

Open Roles: 8 active jobs

Portfolio Health

Growth1 (50%)

Peak1 (50%)

2 total products

Therapeutic Area Focus

Immunology

2 marketed22 pipeline

7 pipeline

2 marketed

2 marketed

2 marketed

Financials (FY2025)

Revenue

$60M1517%

R&D Spend

$111M(186%)39%

Net Income

-$262M

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment

2026

PMID:42274139

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

NCT04445987Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Phase 2

NCT04845620Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Phase 3

Respiratory

2 marketed

Psychiatry

1 marketed

The Journal of dermatological treatment

2026

PMID:42274146

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Arcutis Biotherapeutics(ARQT)

Should You Work at Arcutis Biotherapeutics?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Recent News · Arcutis Biotherapeutics(10)

Open Jobs (8)

Senior Director Supplier Quality

Director HCP Marketing

Senior Manager Regulatory Affairs Advertising & Promotion

Director Regulatory Affairs Advertising & Promotion

Therapeutic Sales Specialist - Baltimore, MD

Sr Manager Business Analytics & Insights

Therapeutic Sales Specialist - Arlington, VA

Sr Medical Science Liaison - Florida

Financials (FY2025)

Hiring Trend

Research Publications(10)